Purpose: Immune checkpoint inhibitors combined with antiangiogenic agents produce
benefits in the treatment of advanced hepatocellular carcinoma (HCC). We investigated the …

Objective Sorafenib is effective in hepatocellular carcinoma (HCC), but patients ultimately
present disease progression. Molecular mechanisms underlying acquired resistance are still …

Background Patients with cirrhosis are at high risk of hepatocellular carcinoma (HCC). The
SEPT9 gene is a key regulator of cell division and tumor suppressor whose …

Background & Aims According to the clonal model of tumor evolution, trunk alterations arise
at early stages and are ubiquitous. Through the characterization of early stages of …

Hepatocellular carcinoma (HCC) is the second cause of death due to malignancy in the
world, following lung cancer. The geographic distribution of this disease accompanies its …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and has a
poor prognosis. Epigenetic modification has been shown to be deregulated during HCC …

Knowledge of the fundamental epigenetic mechanisms governing gene expression and
cellular phenotype are sufficiently advanced that novel insights into the epigenetic control of …

Purpose Early-stage hepatocellular carcinoma (E-HCC) is being diagnosed increasingly,
and in one half of diagnosed patients, recurrence will develop. Thus, it is urgent to identify …

Background and Aims Mutations in TERT (telomerase reverse transcriptase) promoter are
established gatekeepers in early hepatocarcinogenesis, but little is known about other …

In Japan, bezafibrate (BF) is a second‐line agent for primary biliary cholangitis (PBC) that is
refractory to ursodeoxycholic acid (UDCA) treatment. From a retrospective cohort (n= 873) …